These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

474 related articles for article (PubMed ID: 28040660)

  • 1. Quality of life and swallowing with standard chemoradiotherapy versus accelerated radiotherapy and panitumumab in locoregionally advanced carcinoma of the head and neck: A phase III randomised trial from the Canadian Cancer Trials Group (HN.6).
    Ringash J; Waldron JN; Siu LL; Martino R; Winquist E; Wright JR; Nabid A; Hay JH; Hammond A; Sultanem K; Hotte S; Leong C; El-Gayed AA; Naz F; Ramchandar K; Owen TE; Montenegro A; O'Sullivan B; Chen BE; Parulekar WR
    Eur J Cancer; 2017 Feb; 72():192-199. PubMed ID: 28040660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quality of Life and Performance Status From a Substudy Conducted Within a Prospective Phase 3 Randomized Trial of Concurrent Accelerated Radiation Plus Cisplatin With or Without Cetuximab for Locally Advanced Head and Neck Carcinoma: NRG Oncology Radiation Therapy Oncology Group 0522.
    Truong MT; Zhang Q; Rosenthal DI; List M; Axelrod R; Sherman E; Weber R; Nguyen-Tân PF; El-Naggar A; Konski A; Galvin J; Schwartz D; Trotti A; Silverman C; Singh A; Godette K; Bonner JA; Jones CU; Garden AS; Shenouda G; Matthiesen C; Le QT; Bruner D
    Int J Radiat Oncol Biol Phys; 2017 Mar; 97(4):687-699. PubMed ID: 27727066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiotherapy versus transoral robotic surgery and neck dissection for oropharyngeal squamous cell carcinoma (ORATOR): an open-label, phase 2, randomised trial.
    Nichols AC; Theurer J; Prisman E; Read N; Berthelet E; Tran E; Fung K; de Almeida JR; Bayley A; Goldstein DP; Hier M; Sultanem K; Richardson K; Mlynarek A; Krishnan S; Le H; Yoo J; MacNeil SD; Winquist E; Hammond JA; Venkatesan V; Kuruvilla S; Warner A; Mitchell S; Chen J; Corsten M; Johnson-Obaseki S; Eapen L; Odell M; Parker C; Wehrli B; Kwan K; Palma DA
    Lancet Oncol; 2019 Oct; 20(10):1349-1359. PubMed ID: 31416685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single-Arm Phase 2 Trial of Elective Nodal Dose Reduction for Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck.
    Maguire PD; Neal CR; Hardy SM; Schreiber AM
    Int J Radiat Oncol Biol Phys; 2018 Apr; 100(5):1210-1216. PubMed ID: 29452770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quality of Life and Performance Status From a Substudy Conducted Within a Prospective Phase 3 Randomized Trial of Concurrent Standard Radiation Versus Accelerated Radiation Plus Cisplatin for Locally Advanced Head and Neck Carcinoma: NRG Oncology RTOG 0129.
    Xiao C; Zhang Q; Nguyen-Tân PF; List M; Weber RS; Ang KK; Rosenthal D; Filion EJ; Kim H; Silverman C; Raben A; Galloway T; Fortin A; Gore E; Winquist E; Jones CU; Robinson W; Raben D; Le QT; Bruner D
    Int J Radiat Oncol Biol Phys; 2017 Mar; 97(4):667-677. PubMed ID: 27727063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Panitumumab plus radiotherapy versus chemoradiotherapy in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-2): a randomised, controlled, open-label phase 2 trial.
    Giralt J; Trigo J; Nuyts S; Ozsahin M; Skladowski K; Hatoum G; Daisne JF; Yunes Ancona AC; Cmelak A; Mesía R; Zhang A; Oliner KS; VanderWalde A
    Lancet Oncol; 2015 Feb; 16(2):221-32. PubMed ID: 25596659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Standard Radiotherapy With Cisplatin vs Accelerated Radiotherapy With Panitumumab in Locoregionally Advanced Squamous Cell Head and Neck Carcinoma: A Randomized Clinical Trial.
    Siu LL; Waldron JN; Chen BE; Winquist E; Wright JR; Nabid A; Hay JH; Ringash J; Liu G; Johnson A; Shenouda G; Chasen M; Pearce A; Butler JB; Breen S; Chen EX; FitzGerald TJ; Childs TJ; Montenegro A; O'Sullivan B; Parulekar WR
    JAMA Oncol; 2017 Feb; 3(2):220-226. PubMed ID: 27930762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemoradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-1): a randomised, controlled, open-label phase 2 trial.
    Mesía R; Henke M; Fortin A; Minn H; Yunes Ancona AC; Cmelak A; Markowitz AB; Hotte SJ; Singh S; Chan AT; Merlano MC; Skladowski K; Zhang A; Oliner KS; VanderWalde A; Giralt J
    Lancet Oncol; 2015 Feb; 16(2):208-20. PubMed ID: 25596660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acupuncture for Chemoradiation Therapy-Related Dysphagia in Head and Neck Cancer: A Pilot Randomized Sham-Controlled Trial.
    Lu W; Wayne PM; Davis RB; Buring JE; Li H; Macklin EA; Lorch JH; Burke E; Haddad TC; Goguen LA; Rosenthal DS; Tishler RB; Posner MR; Haddad RI
    Oncologist; 2016 Dec; 21(12):1522-1529. PubMed ID: 27511906
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of dysphagia in advanced-stage head-and-neck cancer patients: impact on quality of life and development of a preventive swallowing treatment.
    Carmignani I; Locatello LG; Desideri I; Bonomo P; Olmetto E; Livi L; Le Saec O; Coscarelli S; Mannelli G
    Eur Arch Otorhinolaryngol; 2018 Aug; 275(8):2159-2167. PubMed ID: 29978259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of swallowing and speech problems in daily life after chemoradiation for head and neck cancer based on cut-off scores of the patient-reported outcome measures SWAL-QOL and SHI.
    Rinkel RN; Verdonck-de Leeuw IM; Doornaert P; Buter J; de Bree R; Langendijk JA; Aaronson NK; Leemans CR
    Eur Arch Otorhinolaryngol; 2016 Jul; 273(7):1849-55. PubMed ID: 26071622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long term patient reported swallowing function following chemoradiotherapy for oropharyngeal carcinoma.
    Dixon L; Ramasamy S; Cardale K; Dyker K; Garcez K; Lee LW; McPartlin A; Murray P; Sen M; Slevin N; Sykes A; Prestwich R; Thomson D
    Radiother Oncol; 2018 Sep; 128(3):452-458. PubMed ID: 29937211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized phase III trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas in the Radiation Therapy Oncology Group 0129 trial: long-term report of efficacy and toxicity.
    Nguyen-Tan PF; Zhang Q; Ang KK; Weber RS; Rosenthal DI; Soulieres D; Kim H; Silverman C; Raben A; Galloway TJ; Fortin A; Gore E; Westra WH; Chung CH; Jordan RC; Gillison ML; List M; Le QT
    J Clin Oncol; 2014 Dec; 32(34):3858-66. PubMed ID: 25366680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective evaluation of patient reported swallow function with the Functional Assessment of Cancer Therapy (FACT), MD Anderson Dysphagia Inventory (MDADI) and the Sydney Swallow Questionnaire (SSQ) in head and neck cancer patients.
    Peng LC; Hui X; Cheng Z; Bowers MR; Moore J; Cecil E; Choflet A; Thompson A; Muse M; Kiess AP; Page BR; Gourin CG; Fakhry C; Szczesniak M; Maclean J; Wu P; Cook I; McNutt TR; Quon H
    Oral Oncol; 2018 Sep; 84():25-30. PubMed ID: 30115472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DARS: a phase III randomised multicentre study of dysphagia- optimised intensity- modulated radiotherapy (Do-IMRT) versus standard intensity- modulated radiotherapy (S-IMRT) in head and neck cancer.
    Petkar I; Rooney K; Roe JW; Patterson JM; Bernstein D; Tyler JM; Emson MA; Morden JP; Mertens K; Miles E; Beasley M; Roques T; Bhide SA; Newbold KL; Harrington KJ; Hall E; Nutting CM
    BMC Cancer; 2016 Oct; 16(1):770. PubMed ID: 27716125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quality of Life Analysis of a Radiation Dose-Escalation Study of Patients With Non-Small-Cell Lung Cancer: A Secondary Analysis of the Radiation Therapy Oncology Group 0617 Randomized Clinical Trial.
    Movsas B; Hu C; Sloan J; Bradley J; Komaki R; Masters G; Kavadi V; Narayan S; Michalski J; Johnson DW; Koprowski C; Curran WJ; Garces YI; Gaur R; Wynn RB; Schallenkamp J; Gelblum DY; MacRae RM; Paulus R; Choy H
    JAMA Oncol; 2016 Mar; 2(3):359-67. PubMed ID: 26606200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Patient- and Practitioner-Reported Toxic Effects Associated With Chemoradiotherapy for Head and Neck Cancer.
    Falchook AD; Green R; Knowles ME; Amdur RJ; Mendenhall W; Hayes DN; Grilley-Olson JE; Weiss J; Reeve BB; Mitchell SA; Basch EM; Chera BS
    JAMA Otolaryngol Head Neck Surg; 2016 Jun; 142(6):517-23. PubMed ID: 27149571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute and chronic changes in swallowing and quality of life following intraarterial chemoradiation for organ preservation in patients with advanced head and neck cancer.
    Murry T; Madasu R; Martin A; Robbins KT
    Head Neck; 1998 Jan; 20(1):31-7. PubMed ID: 9464950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): an open-label phase 3 randomised trial.
    Bourhis J; Sire C; Graff P; Grégoire V; Maingon P; Calais G; Gery B; Martin L; Alfonsi M; Desprez P; Pignon T; Bardet E; Rives M; Geoffrois L; Daly-Schveitzer N; Sen S; Tuchais C; Dupuis O; Guerif S; Lapeyre M; Favrel V; Hamoir M; Lusinchi A; Temam S; Pinna A; Tao YG; Blanchard P; Aupérin A
    Lancet Oncol; 2012 Feb; 13(2):145-53. PubMed ID: 22261362
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact on Health-Related Quality of Life of Induction Chemotherapy Compared With Concurrent Cisplatin and Radiation Therapy in Patients With Head and Neck Cancer.
    Adkins D; Ley J; Oppelt P; Gay HA; Daly M; Paniello RC; Jackson R; Pipkorn P; Rich J; Zevallos J; Trinkaus K; Thorstad W
    Clin Oncol (R Coll Radiol); 2019 Sep; 31(9):e123-e131. PubMed ID: 31147146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.